Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
Asset
(866)
News
(637)
SEC filing
(367)
Event
(219)
Landing page
(63)
Person
(51)
Governance committee
(8)
Filter by content year
2024
(111)
2023
(303)
2022
(594)
2021
(446)
2020
(496)
2019
(64)
2018
(11)
2017
(4)
2016
(15)
2015
(16)
Filter by form group
Filter by category
Filter by category
Search
News
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
SEC Filings
Form 6-K
Asset
Q3 2020 Presentation
Q3 2020 Presentation
1.4 MB
Asset
BNTX 3Q 2020 Presentation
BNTX 3Q 2020 Presentation
1.4 MB
News
Pfizer und BioNTech schließen Liefervereinbarung mit der EU über 200 Millionen Dosen ihres mRNA-basierten Impfstoffkandidaten BNT162b2 gegen COVID-19
News
Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19
SEC Filings
Form 6-K
Asset
Q3 2020 Financial Report
Q3 2020 Financial Report
463.3 KB
Asset
BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China
PDF Version
153.7 KB
News
BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China
Pagination
Previous page
‹‹
Page 2
Next page
››